Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
Key Highlights
- ➤Aquestive will report Q3 2026 financial results after market close November 3.
- ➤Management will host the Q3 2026 investor conference call November 4 at 8:00 a.m. ET.
- ➤Anaphylm remains under FDA regulatory review for potential approval in Type I allergic reactions.
- ➤AQST-108 topical gel is advancing through clinical development for potential dermatological indications.
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report financial results for the third quarter ended September 30, 2026, and provide an update on recent developments in its business after market close on Tuesday, November 3, 2026.
Management will host a conference call for investors at 8:00 a.m. ET on Wednesday, November 4, 2026. To participate, please register in advance at https://register-conf.media-server.com/register/BI4103ddb2ad704c5e815844e1e14ff5c8 to obtain a local or toll-free telephone number and your personal PIN.
Get started
Create a free account to read the full story.